This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Julia F. Slejko, PhD
Advertisement
Articles by Julia F. Slejko, PhD
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Advertisement
Latest Updated Articles
- Impact of Formulary Restrictions on Medication Intensification in Diabetes Treatment
Published: May 7th 2018 | Updated:
- Cost-effectiveness of Diabetes Treatment Sequences to Inform Step Therapy Policies
Published: March 10th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
